Phase 2 Study of Ruxolitinib in Patients with Chronic Neutrophilic Leukemia or Atypical Chronic Myeloid Leukemia

Background Chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) are rare myeloid malignancies with an estimated median survival of 2 years. No effective therapy has been established. The majority of CNL and

Saved in:
Bibliographic Details
Published in:Blood 2018-11, Vol.132 (Supplement 1), p.350-350
Main Authors: Dao, Kim-Hien, Collins, Robert H., Cortes, Jorge E., Deininger, Michael W., Druker, Brian J., Gotlib, Jason R., Macey, Tara Alyson, Oh, Stephen T, Tyner, Jeffrey W., Winton, Elliott F.
Format: Article
Language:English
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) are rare myeloid malignancies with an estimated median survival of 2 years. No effective therapy has been established. The majority of CNL and
ISSN:0006-4971
1528-0020
DOI:10.1182/blood-2018-99-119476